Phage display, a 60-year-old technology for antibody screening, expresses antibodies on phage surface proteins such as pIII and pVIII. pVIII is most widely used with about 3,000 copies to boost signals. It offers a large library capacity of 1E10–1E11. Using E. coli expression, it features simple operation and short cycles. NabLife’s NabLib® platform provides phage display-based antibody discovery and engineering for drug development.
Technical principle：
|
Phage Display Technical principle |
Dual-function plasmid system |
 |
 |
Service process：
Comparison of Antibody Display Techniques：
Service Features：
|
|
|
|
|
 |
 |
 |
 |
|
Efficient antibody screening
Obtain the antibody sequence within 4 weeks
|
One step at a time
Thermal stability test
|
Switch freely
Phage display - Antibody secretion
|
Extensive storage capacity
Meet the requirements of antibody screening
|
Representative cases 1:
In this case study, we performed nanobody screening against the target provided by the client. Multiple nanobody candidates were identified during screening, exhibiting affinity and cellular neutralizing activity comparable to the positive control (a marketed drug molecule). Beyond meeting predefined biological functional criteria, this panel of nanobodies demonstrated excellent cross-reactivity toward human and cynomolgus monkey antigens.
|
Binding ELISA |
Blocking ELISA |
Flow cytometry |
|
|
|
|
